Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7977842 | 0.89 | DPP4 (0.64) | DPP4HDAC8PTPN1FAPPREP | |
| SCHEMBL7995839 | 0.89 | DPP4 (0.64) | DPP4HDAC8PTPN1FAPPREP | |
| SCHEMBL864979 | 0.86 | HDAC8 (0.48) | HDAC8PTPN1 | |
| SCHEMBL7988406 | 0.85 | DPP4 (0.48) | DPP4HDAC8PTPN1FAPPREP | |
| SCHEMBL7988401 | 0.85 | DPP4 (0.48) | DPP4HDAC8PTPN1FAPPREP | |
| SCHEMBL7992051 | 0.85 | DPP4 (0.50) | DPP4HDAC8PTPN1FAPPREP | |
| SCHEMBL7992048 | 0.85 | DPP4 (0.50) | DPP4HDAC8PTPN1FAPPREP | |
| SCHEMBL7989672 | 0.85 | HDAC8 (0.50) | DPP4HDAC8FAPPREP | |
| SCHEMBL7988600 | 0.84 | HDAC8 (0.52) | DPP4HDAC8PTPN1PREP | |
| SCHEMBL7989903 | 0.84 | HDAC8 (0.53) | DPP4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | DPP4 217/4885HDAC8 2636/4885PTPN1 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.